An Algorithm Addressing the Problem of Overdiagnosis of Clostridioides difficile Infections in Hematopoietic Stem Cell Transplantation Recipients: Effects on C. difficile Infection Rates and Patient Outcomes
- PMID: 37086852
- DOI: 10.1016/j.jtct.2023.04.010
An Algorithm Addressing the Problem of Overdiagnosis of Clostridioides difficile Infections in Hematopoietic Stem Cell Transplantation Recipients: Effects on C. difficile Infection Rates and Patient Outcomes
Abstract
Diarrhea of other causes and Clostridioides difficile colonization are common in patients hospitalized for hematopoietic stem cell transplantation (HSCT). It has been well recognized that these issues tend to decrease the specificity of stool testing for C. difficile infection (CDI). The best way to address this problem is uncertain. In September 2018, we initiated a project with the goal of addressing the apparent problem of overdiagnosis of CDIs in our HSCT population. Using the quality improvement tool Model for Improvement, we introduced a C. difficile stool testing and CDI diagnosis algorithm with the aim of decreasing unnecessary inpatient CDI diagnoses and treatments. In this study, we examined the effects of the algorithm. We reviewed all HSCT admissions for the 2 years before introduction of the algorithm and the subsequent 3 years, recording all stool submissions for C. difficile determination and CDI. At the close of the study, we recruited our advanced practice providers (APPs) to review all CDIs following algorithm initiation and provide feedback on the ease of use of the algorithm and potential improvements to the overall process. Stool submissions for C. difficile determination decreased from 38.0/1000 to 20.6/1000 inpatient days (P < .001) and CDI diagnoses decreased from 5.5/1000 to 2.4/1000 days (P = .007). Patients admitted for a first allogeneic HSCT, first autologous HSCT, or HSCT readmission showed similar proportionate reductions. No detrimental effects on hospital length of stay, overall survival, progression-free survival, rate of readmission post-HSCT, incidence of acute graft-versus-host disease, or incidence of recurrent CDI were noted following algorithm introduction. A strategy of education, monitoring/feedback, and ease of algorithm access proved effective in inducing provider compliance. APPs rated the algorithm high on ease of use. We conclude that the use of an algorithm defining criteria for C. difficile testing, diagnosis, and treatment was associated with significantly decreased CDI diagnoses on a HSCT inpatient unit without apparent adverse effects.
Keywords: Adverse events; Algorithm; Clostridioides difficile; Hematopoietic stem-cell transplantation; Model for Improvement.
Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Are Clostridioides difficile infections being overdiagnosed in hematopoietic stem cell transplant recipients?Transpl Infect Dis. 2020 Aug;22(4):e13279. doi: 10.1111/tid.13279. Epub 2020 Apr 8. Transpl Infect Dis. 2020. PMID: 32196881
-
Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients.Clin Infect Dis. 2012 Apr;54(8):1053-63. doi: 10.1093/cid/cir1035. Epub 2012 Mar 12. Clin Infect Dis. 2012. PMID: 22412059 Free PMC article.
-
Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.Transplant Cell Ther. 2021 Feb;27(2):176.e1-176.e8. doi: 10.1016/j.jtct.2020.10.009. Epub 2020 Dec 11. Transplant Cell Ther. 2021. PMID: 33830032
-
Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation.Curr Hematol Malig Rep. 2014 Mar;9(1):85-90. doi: 10.1007/s11899-013-0193-y. Curr Hematol Malig Rep. 2014. PMID: 24390550 Review.
-
Prevalence of Clostridium difficile Infection in the Hematopoietic Transplantation Setting: Update of Systematic Review and Meta-Analysis.Front Cell Infect Microbiol. 2022 Feb 21;12:801475. doi: 10.3389/fcimb.2022.801475. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35265530 Free PMC article.
Cited by
-
Diagnosis of Clostridioides difficile infection and impact of testing.J Med Microbiol. 2024 Dec;73(12):001939. doi: 10.1099/jmm.0.001939. J Med Microbiol. 2024. PMID: 39625750 Free PMC article. Review.
-
Oral Vancomycin to Prevent Clostridioides difficile in Stem Cell Transplant Recipients: The Last Frontier in Antimicrobial Prophylaxis.Open Forum Infect Dis. 2024 Oct 14;11(11):ofae623. doi: 10.1093/ofid/ofae623. eCollection 2024 Nov. Open Forum Infect Dis. 2024. PMID: 39498173 Free PMC article. No abstract available.
-
Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10).EClinicalMedicine. 2025 Aug 7;87:103371. doi: 10.1016/j.eclinm.2025.103371. eCollection 2025 Sep. EClinicalMedicine. 2025. PMID: 40823499 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources